Prescription weight loss drugs, like GLP-1 agonists and orlistat, offer effectiveness for some individuals and have proven effects the market has taken notice of. These drugs focus on curbing appetite, which investors in weight loss drug stocks have noticed. These drugs, combined with exercise and other diet enhancements, have proven effective. However, with FDA approvals for only certain conditions (depending on the label) and Medicare coverage differing by insurance provider, there’s still some uncertaint ...

The pharmaceutical industry is scrambling for breakthroughs in weight loss treatment. Demand for medications such as Ozempic, Wegovy, Mounjaro, and Zepbound is rising. All of these diabetes and obesity treatments are developed by just two companies: Novo Nordisk (NVO -0.41%) and Eli Lilly (LLY -0.34%). The two pharma giants are competing intensely.While Novo Nordisk currently holds a commanding lead in the glucagon-like peptide 1 (GLP-1) market, Lilly may have just outmaneuvered its rival. Let's dig into a ...

Eli Lilly (LLY -0.34%) has become a giant in what may be a $100 billion market a few years from now. I'm talking about the world of weight loss drugs.Doctors have been prescribing Mounjaro and the newly approved Zepbound to patients aiming to shed pounds, and that's brought in billions in revenue to the pharma giant. These drugs work by acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormone pathways involved in the digestion process.But in the coming ye ...

Novo Nordisk (NVO -1.14%) and Eli Lilly (LLY 1.33%) are the top two healthcare stocks in the world based on market cap. Their diabetes and weight loss medications are a big reason these have been among the best healthcare investments to own over the past few years. Today, Eli Lilly is the larger of the two companies, with a market cap of more than $700 billion. Novo Nordisk, however, isn't too far behind, sporting a valuation about $600 billion. And there are some recent catalysts that suggest that gap coul ...

In the latest trading session, Eli Lilly (LLY) closed at $772.78, marking a +1.33% move from the previous day. This change outpaced the S&P 500's 0.57% gain on the day. Meanwhile, the Dow experienced a rise of 0.83%, and the technology-dominated Nasdaq saw an increase of 0.39%.The the stock of drugmaker has fallen by 2.48% in the past month, lagging the Medical sector's gain of 0.13% and the S&P 500's gain of 2.97%.The investment community will be paying close attention to the earnings performance of Eli Li ...

INDIANAPOLIS, INDIANA - MARCH 17: A sign with the company logo sits outside of the headquarters ... [+] campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)Getty ImagesEli Lilly stock (NYSE: LLY) has seen phenomenal gains of 345% from levels of $170 in early January 2021 to around $755 now, vs. an increase of about 35% for the S&P 500 over this roughly three-year period. This can primarily be attributed to a significant 236% rise in the company’s P/ ...

Every huge drugmaker was once a much smaller drugmaker. We don't even have to go back too many years to see where Eli Lilly (LLY 1.13%) and Novo Nordisk (NVO 0.39%), currently the two biggest pharma companies on the planet, were only a fraction of their current sizes. The main way small drugmakers become large is by launching successful new products. Madrigal Pharmaceuticals (MDGL 4.76%) should soon have its first taste of such success with the U.S. Food and Drug Administration (FDA) approving Rezdiffra for ...

Growth stocks are rising, offering stellar gains so far this year. The tech-heavy S&P 500 continues to post new highs, with investors shrugging off inflation concerns. Moreover, with interest rate cuts likely in the next few months, expect growth stocks to continue rallying.However, not all growth stocks are worth investing in. In fact, concerns surrounding an AI bubble warrant caution and investment in stocks offering long-term value. Hence, in such a scenario, it is always a great idea to consider opinion ...

As great of an investment as Eli Lilly (LLY -0.86%) is during the age of Zepbound, its newest and hottest weight-loss drug, there are many other magnificent opportunities out there right now, and it'd be a disservice to your portfolio to ignore them entirely.Take Iovance Biotherapeutics (IOVA -2.11%), for example. Its shares are up by 110% over the last 12 months, and if you can adopt a long-term mindset, the party could be just getting started. Here's why it's worth thinking about buying.This stock has cat ...

When a company's big plans go awry, it's always worth reconsidering the merits of an investment. On March 8, regulators at the Food and Drug Administration (FDA) gave Eli Lilly (LLY -0.86%) an unwelcome surprise. Rather than granting approval to commercialize the company's Alzheimer's disease drug donanemab as expected, the FDA opted to delay its decision.Instead, the FDA planned to call an advisory committee composed of third-party experts who would discuss and deliver a non-binding vote on whether to appr ...